A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

Authors

Xiangcheng Li (ORCID: https://orcid.org/0000-0002-8878-7332)
Chang Xian Li (ORCID: https://orcid.org/0000-0002-6485-3534)
Yonghua Xu (ORCID: https://orcid.org/0000-0002-3632-8900)
Bin Zhang (ORCID: https://orcid.org/0000-0002-6286-6227)
Yuan Cheng (ORCID: https://orcid.org/0000-0003-4173-293X)

Institutions

Xuzhou Medical College (CN)
Nantong University (CN)
Nanjing General Hospital of Nanjing Military Command (CN)
Yancheng First People's Hospital (CN)
Jiangsu Province Hospital (CN)
Nanjing Medical University (CN)
Nanjing University (CN)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-05-28
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps4220
Primary Topic: Cholangiocarcinoma and Gallbladder Cancer Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

Xiangcheng Li, Chang Xian Li, Yonghua Xu, Bin Zhang et al.

May 28, 2025

Journal of Clinical Oncology

Cholangiocarcinoma and Gallbladder Cancer Studies

article

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

Xiangcheng Li, Chang Xian Li, Yonghua Xu, Bin Zhang, Yuan Cheng

May 28, 2025article en

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(16_suppl)

Xuzhou Medical College (CN), Nantong University (CN), Nanjing General Hospital of Nanjing Military Command (CN), Yancheng First People's Hospital (CN), Jiangsu Province Hospital (CN), Nanjing Medical University (CN), Nanjing University (CN)

Openalex Percentile: Top 79%

Cholangiocarcinoma and Gallbladder Cancer Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE. — Xiangcheng Li, Chang Xian Li, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS